ClinicalTrials.gg
Not yet recruitingNCT06891521Updated Mar 24, 2025

Electroacupuncture for Preventing Adverse Events of Cancer Immunotherapy

A Phase 2 interventional study of Electroacupuncture in Cancer and Adverse Events, sponsored by Qinghai Red Cross Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Qinghai Red Cross Hospital · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aims to investigate the preventive effects of electroacupuncture on immune-related adverse events (irAEs) in patients with malignant solid tumors at the neoadjuvant stage, locally advanced, unresectable, or metastatic stages, who are receiving immune checkpoint inhibitors (ICIs) monotherapy, ICIs combined with anti-angiogenic agents, or ICIs combined with chemotherapy. The study will evaluate the efficacy, safety and mechanisms of electroacupuncture in preventing irAEs in a multicenter setting.

Read the detailed description

This study is a prospective, multicenter, open-label, single-arm clinical trial aimed at collecting data from patients with malignant solid tumors at the neoadjuvant stage, locally advanced, unresectable, or metastatic stages, who are receiving immune checkpoint inhibitors (ICIs) monotherapy, ICIs combined with anti-angiogenic agents, or ICIs combined with chemotherapy. The objective is to evaluate the efficacy and safety of electroacupuncture in preventing immune-related adverse events (irAEs). Patients who meet the inclusion and exclusion criteria will be formally enrolled after screening and providing informed consent. Eligible patients will receive electroacupuncture treatment, with the intervention occurring on the day before and the first day of each ICIs treatment cycle. During the treatment period, the incidence, severity, and timing of irAEs will be monitored through follow-up assessments. Additionally, questionnaires will be collected to evaluate the impact of electroacupuncture on quality of life. Blood samples will be collected for analysis of changes in inflammatory cytokines and peripheral blood lymphocyte subset proportions. The study will also assess primary and secondary outcomes, as well as adverse events.

02

Conditions studied

  • Cancer
  • Adverse Events

Browse trials for

Keywords

  • Electroacupuncture
  • immunotherapy
  • immune-related adverse events (irAEs)
  • malignant tumors
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 123 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Qinghai Red Cross Hospital is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years, any gender, any nationality.
  2. (ECOG) performance status of 0-2.
  3. A definitive diagnosis of malignant tumor confirmed by pathology, and no previous treatment with /PD-L1 inhibitors.
  4. Patients who are receiving their first treatment with PD-1/PD-L1 inhibitors monotherapy, PD-1/PD-L1 inhibitors combined with anti-angiogenic agents, or combined chemotherapy.
  5. Expected survival of more than 3 months.
  6. Normal bone marrow and organ function.
  7. Premenopausal women must use adequate .
  8. Written obtained from the patient prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously received or are currently receiving immunotherapy monotherapy, immunotherapy combined with chemotherapy, or immunotherapy combined with targeted therapy.
  2. Patients who have undergone acupuncture, radiotherapy, or surgery within 4 weeks prior to the start of treatment.
  3. Patients who have received any dose of systemic treatment within 72 hours prior to Day 1 of Cycle 1.
  4. Patients with active systemic diseases within the past 2 years (such as but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitaryitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with a history of vitiligo or asthma in childhood who have been in complete remission with no intervention in adulthood may be included; subjects requiring bronchodilator medical intervention should be excluded), diagnosed with immunodeficiency or treated with therapy within the past week, (HIV) (+), history of non-infectious pneumonia treated with glucocorticoids, pneumonia, active tuberculosis, active or C virus infection, or currently undergoing any systemic treatment for active infections.
  5. Significant abnormal laboratory values ( count, , free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone(TSH), adrenocorticotropic hormone (ACTH), morning cortisol, (HbA1c), C-peptide, autoantibodies, (ALT), aspartate aminotransferase (AST), alkaline phosphatase, /international normalized ratio (PT/INR), serum , amylase, lipase, CRP).
  6. Skin diseases or inflammatory skin reactions that may interfere with clinical trial outcomes.
  7. Patients who have developed lymphedema at the site of acupuncture stimulation after receiving any acupuncture treatment.
  8. Patients who fear electroacupuncture stimulation or are allergic to stainless steel needles.
  9. Patients with psychiatric disorders, or those taking any antipsychotic or antidepressant medications.
  10. Any unresolved skin toxicity caused by previous chemotherapy or radiotherapy, except for hair loss.
  11. Patients with diabetes.
  12. Any other diseases, metabolic disorders, physical examination results, or clinical laboratory findings that raise reasonable suspicion of a disease or condition that may affect the interpretation of the outcomes or put the participant at high risk for treatment complications.
  13. Pregnant or breastfeeding women, or women planning to become pregnant during the study period.
  14. Severe medical or psychiatric conditions.
  15. Any patient deemed unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
123 participants (estimated)

Study arms

  • Experimental
    Electroacupuncture group

    Patients received electroacupuncture therapy on the day before and the first day of each ICIs treatment cycle. Intervention: The patient received electroacupuncture and standard antitumor therapy.

    Procedure: Electroacupuncture

Interventions

  • ProcedureElectroacupuncture

    Patients received electroacupuncture on the day before and the first day of each ICIs treatment cycle. The electroacupuncture points selected Zusanli (ST36), Quchi (LI11), and Hegu (LI4). Patients will be positioned supine, and the acupuncturist will disinfect the local skin at the acupuncture points using 75% ethanol on cotton balls. A disposable acupuncture needle (0.3mm × 40mm) will be inserted using either a single-hand or double-hand needling technique, with rapid, direct insertion. Once the needle reaches a depth of approximately 0.5 cun, the technique of lifting, thrusting, twirling, and rotating will be applied. After obtaining "de qi", the needles will be retained for 30 minutes. Needling will be performed once every 10 minutes, and the needling technique used will be a balanced reinforcing and reducing method. Electroacupuncture will be applied using a dense-wave form, with a frequency of 2 Hz and an intensity not exceeding 10 mA.

06

What researchers measure

Primary outcomes

  1. The overall incidence of any grade of immune-related adverse events (irAEs).

    IrAEs are defined as any adverse events potentially related to immune mechanisms that occur during or after ICIs treatment. Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 48 weeks.

Secondary outcomes

  1. The incidence of Grade ≥3 immune-related adverse events (irAEs).

    IrAEs are defined as any adverse events potentially related to immune mechanisms that occur during or after ICIs treatment. Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 48 weeks.

  2. The time to onset of Grade ≥3 immune-related adverse events (irAEs).

    The time to onset is defined as the period from the initiation of immune checkpoint inhibitor (ICIs) treatment to the occurrence of the immune-related adverse event. Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 48 weeks.

  3. The time to onset of any grade of immune-related adverse events (irAEs).

    The time to onset is defined as the period from the initiation of immune checkpoint inhibitor (ICIs) treatment to the occurrence of the immune-related adverse event. Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 48 weeks.

  4. The incidence of any grade and Grade ≥3 immune-related adverse events (irAEs) associated with ICIs combination therapy.

    IrAEs are defined as any adverse events potentially related to immune mechanisms that occur during or after ICIs treatment. Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 48 weeks.

  5. The incidence of any grade and Grade ≥3 treatment-related adverse events (TRAEs) associated with ICIs combined with chemotherapy.

    TRAEs are defined as any adverse events caused by ICIs combined with chemotherapy during or after the treatment period. Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 48 weeks.

  6. The incidence of any grade and Grade ≥3 immune-related adverse events (irAEs) associated with ICIs monotherapy.

    IrAEs are defined as any adverse events potentially related to immune mechanisms that occur during or after ICIs treatment. Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 48 weeks.

  7. The incidence of any grade and Grade ≥3 treatment-related adverse events (TRAEs) associated with ICIs combined with anti-angiogenic agents.

    TRAEs are defined as any adverse events caused by ICIs combined with anti-angiogenic agents during or after the treatment period. Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 48 weeks.

  8. The incidence of any grade and Grade ≥3 hyperthyroidism and hypothyroidism.

    Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 48 weeks.

  9. The incidence of any grade and Grade ≥3 rash.

    Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 48 weeks.

  10. The incidence of any grade and Grade ≥3 hepatitis.

    Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 48 weeks.

  11. The incidence of any grade and Grade ≥3 pneumonia.

    Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 48 weeks.

  12. The incidence of any grade and Grade ≥3 abnormal blood glucose levels.

    Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: 48 weeks.

  13. Comparison of biomarker changes before and after electroacupuncture treatment.

    The differences in biomarkers will be monitored through hematological parameters, including: inflammatory biomarkers such as C-reactive protein (CRP), procalcitonin (PCT), inflammatory cytokines like IL-1β, IL-6, IL-10, TNF-α, IFN-γ, and changes in the proportions of peripheral blood lymphocyte subsets (CD4+, CD8+ T cells, natural killer cells (NK cells), regulatory T cells (Treg cells), and myeloid-derived suppressor cells (MDSCs)), as well as tumor markers.

    Time frame: 48 weeks.

  14. The incidence of adverse events related to electroacupuncture treatment.

    Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 to determine the proportion of side effects associated with electroacupuncture.

    Time frame: 48 weeks.

  15. The evaluation of the difference in quality of life before and after electroacupuncture treatment.

    Quality of life will be assessed using the EuroQol Five-Dimensional Questionnaire (EQ-5D-5L). EQ-5D-5L is a standardized tool for assessing health-related quality of life, which includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels describing an individual's functional or well-being status in a specific area. Additionally, the EQ-5D-5L includes a visual analogue scale, allowing individuals to rate their overall health status on a scale from 0 (worst health) to 100 (best health).

    Time frame: 48 weeks.

  16. 16.Adherence to electroacupuncture treatment.

    Time frame: 48 weeks.

07

Study locations

1 site
  • Qinghai, China, Qinghai Red Cross Hospital
    Xining, Qinghai 810000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Mar 2027, 23 months later.

Of 337 non-industry phase 2 interventional studies under Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 99. This study's planned 23 months is below that.

Counting every sponsor, half of 517 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 24, 2025
StartEst.
Mar 20, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jun 1, 2028
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06891521
Lead sponsor
Qinghai Red Cross Hospital
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Mar 20, 2025 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Mar 24, 2025

Study contacts

QiuXia Dong, Dr.
Contact
2816278916@qq.com
+86 0971-8267613

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion